1. Introduction {#sec1}
===============

Calcific uremic arteriolopathy (CUA), otherwise termed calciphylaxis, characteristically arises in the setting of end stage renal failure and hyperparathyroidism. Calcific arteriolopathy in the setting of normal renal function is a rare entity termed nonuremic calcific arteriolopathy (NUCA). Both NUCA and CUA are caused by microvascular occlusion secondary to calcium deposition in the vessels of the skin and subcutaneous fat. Given the high morbidity and mortality associated with NUCA, recognition and timely diagnosis are essential for patient management.

2. Case {#sec2}
=======

An 82-year-old woman from rural Australia admitted to hospital for an exacerbation of congestive cardiac failure (CCF) developed intensely painful, flesh colored, subcutaneous nodules on both lower legs and left thigh on a background of livedo racemosa. The nodules coincided with a creatinine rise from 96 *μ*mol/L to 120 *μ*mol/L ([Table 1](#tab1){ref-type="table"}) following aggressive diuresis with frusemide for CCF management. Frusemide was subsequently reduced and renal function normalized. Over the subsequent weeks the nodules ulcerated and took on a serpiginous form.

The patient\'s comorbidities were rheumatoid arthritis, atrial fibrillation, chronic obstructive pulmonary disease, mitral valve replacement (bovine), hypertension, and hypercholesterolemia. Her medications were frusemide, methotrexate 5 mg/week, prednisolone 2.5 mg/day, spironolactone, oxycodone, rabeprazole, potassium, warfarin, salbutamol, budesonide, and formoterol. She had been on the same dose of warfarin for many years and had never smoked cigarettes.

Physical examination showed an afebrile, haemodynamically stable, elderly woman in severe pain from the leg ulcerations. Multiple deep serpiginous ulcerations with overlying necrotic eschars and surrounding macular erythema were present on both lower legs ([Figure 1](#fig1){ref-type="fig"}). A new subcutaneous flesh colored nodule with surrounding erythema was present on her left lateral thigh. Livedo racemosa was present on her upper and lower legs bilaterally.

Deep wedge incisional biopsies taken from the left thigh nodule and calf showed panlobular infarction of subcutaneous fat with extensive mural calcification of small and medium sized vessels within the pannus, with luminal occlusion ([Figure 2](#fig2){ref-type="fig"}). The left calf showed epidermal and dermal necrosis and ulceration. No features of vasculitis were seen. Direct immunofluorescence was negative. Laboratory investigations ([Table 1](#tab1){ref-type="table"}) showed an elevated intact parathyroid hormone (PTH) 17.7 pmol/L, low urine calcium 0.9 mmol/24 hr, and the aforementioned creatinine elevation. Serum calcium, phosphate, vitamin D, and urea were normal. Plain X-rays of the legs showed extensive vascular calcification bilaterally throughout the whole legs including the iliac, femoral, popliteal, and tibial vessels ([Figure 3](#fig3){ref-type="fig"}). Abdominal ultrasound showed areas of bilateral medullary nephrocalcinosis. Thyroid ultrasound showed a colloid cyst; the parathyroid glands were not visualized. Nuclear imaging of the parathyroid glands showed no abnormality. These clinical, radiological, and histopathological findings were consistent with a diagnosis of NUCA.

The patient was commenced on doxycycline 50 mg/day and was given an infusion of Zoledronic acid 5 mg. Warfarin was ceased and the patient was commenced on rivaroxaban. There were no new nodules 6 months after the initial episode and the established erosions were healing slowly.

3. Discussion {#sec3}
=============

NUCA is a rare obstructive vasculopathy caused by calcium deposition within the lumen of small and medium sized blood vessels. In the absence of renal failure, identified risk factors are hypercoagulable states, malignancy, hyperparathyroidism, connective tissue disease, corticosteroids, vitamin D deficiency, calcium based phosphate binders, warfarin, obesity, and diabetes \[[@B1]--[@B5]\]. This patient\'s risk factors were gender, hyperparathyroidism, connective tissue disease, corticosteroid, and warfarin use. Although risk factors for NUCA have been identified the pathogenesis remains poorly understood.

In CUA chronic renal failure causes excess phosphate, which binds with calcium in the blood resulting in blood vessel damage. Reduced vitamin D levels result in increased PTH production. As bones become resistant to PTH the parathyroid glands enlarge to produce more PTH and calcium levels in the blood increase. Although the initial mechanism resulting in calcium deposition in NUCA is not as well characterised as CUA a final common pathway for both CUA and NUCA has been proposed. This pathway involves elevated nuclear factor kB, leading to vascular calcification and thrombosis \[[@B4]\]. Via this pathway, chronic inflammation, impaired liver function, estrogens, parathyroid hormone abnormalities, warfarin, and glucocorticoids may all contribute to the disease.

In this case, given the normal renal function, calcium, phosphate, and vitamin D levels, the elevated PTH represents tertiary hyperparathyroidism. The initial creatinine rise was attributed to hypovolemia caused by aggressive CCF management. Satellite purpuric ulcerations with central overlying necrosis crusts, present in this case, typify the clinical lesions of NUCA. Livedo reticularis or racemosa is usually present on the legs and may precede ulcerations. Clinicopathological correlation is essential for a diagnosis of NUCA.

The characteristic histological features of NUCA, as evident in this case, are calcification of small-medium sized cutaneous vessels, intimal fibrosis, intravascular thrombi, and diffuse calcification of small capillaries in the fat. There may be calcification of adipocytes. Epidermal and dermal ulceration give rise to the typical clinical features of NUCA. Investigations such as plain film X-rays or bone scintigraphy can show arteriolar calcification which may aid diagnosis or monitoring of treatment effects \[[@B6]\].

The management of NUCA involves elimination of identifiable precipitants, adequate analgesia, and early treatment. Meticulous wound management decreases infection risk, and surgical debridement may be warranted. Recent research has suggested that changing warfarin to low molecular weight heparin may be beneficial \[[@B5]\]. Rivaroxaban rather than low molecular weight heparin replaced warfarin in this case due to atrial fibrillation. Other reported treatments are calcimimetic agents, bisphosphonates, hyperbaric oxygen, low dose tissue plasminogen activator, and doxycycline \[[@B8]\]. There is limited evidence for intravenous sodium thiosulfate for its antioxidative properties and ability to increase calcium solubility in NUCA \[[@B7]\].

4. Conclusion {#sec4}
=============

This rare case of NUCA in an 82-year-old Caucasian woman coincided with her hospitalization for the management of her CCF. Her risk factors were gender, connective tissue disease, hyperparathyroid level, glucocorticoid use, and warfarin use. Clinical, histological, and radiological evidence were consistent with a diagnosis of NUCA with no sinister precipitating factors found. The patient improved with meticulous wound care, analgesia, doxycycline 50 mg/day, Zoledronic acid 5 mg, and warfarin cessation. Given the rarity of the disease dermatologists and patients alike would benefit from a greater awareness of NUCA.

CUA:

:   Calcific uremic arteriolopathy
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:   Congestive cardiac failure
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:   Nonuremic calcific arteriolopathy
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:   Parathyroid hormone.
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![Necrotic ulceration on lower legs.](CRIDM2017-6831703.001){#fig1}

![Biopsy left calf, illustrating arteriolar calcification in subcutis.](CRIDM2017-6831703.002){#fig2}

![X-ray illustrating calcification of the femoral and popliteal vessels.](CRIDM2017-6831703.003){#fig3}

###### 

Blood results.

  Test                   02.08.2015   21.09.2015   Normal range
  ---------------------- ------------ ------------ ---------------------
  Haemoglobin            138          129          115--160 g/L
  White cell count       7.0          7.4          4--11 × 10^9^
  Platelets              251          220          150--400 × 10^9^
  Neutrophils            5.26         6.02         1.8--7.5 × 10^9^
  Urea                   6.7          12.6         2.5--7.5 mmol/L
  Creatinine             96           120          45--90 *μ*mol/L
  GFR est                48           36           \>90 Mls/min
  Glucose                5.0          6.6          3.5--5.5 mmol/L
  Osm-calc               291          290          280--300 mOsm/kg
  Bilirubin total        25           23           2--20 *μ*mol/L
  ALT                    14           29           9--33 U/L
  Alkaline phosphatase   101          140          30--110 U/L
  New GGT                295          502          9--56 g/L
  Protein                69           67           69--80 g/L
  Albumin                41           43           33--50 g/L
  ESR                    32           43           1--40 mm/hr
  CRP                    7.3                       \<6 Mg/L
  ACE level (Buhlmann)   49.8                      20--70 U/L
  Calcium                             2.36         2.1--2.6 mmol/L
  Corrected calcium                   2.42         2.1--2.6 mmol/L
  Phosphate                           1.39         0.75--1.50 mmol/L
  Intact serum PTH                    17.7         1.6--7.2 pmol/L
  25-OH vitamin D                     82           \<60 nmol/L
  Urinary Creatinine                  5.7          5.3--15.9 mmol/24 h
  Urinary calcium                     0.9          2.5--7.5 mmol/24 h
  Cold agglutinin                     Negative      
  Cryoglobulin                        Negative      
  C3                                  1.58         0.75--1.61 g/L
  C4                                  0.44 H       0.13--0.40 g/L
  IgG                                 5.3          6.5--15.2 g/L
  IgA                                 1.06         0.76--3.89 g/L
  IgM                                 0.6          0.3--2.3 g/L
  ANA speckled                        1 : 80       Negative
  ENA                                 Negative     \<30 AU/mL
  dsDNA                               5            \<40 IU/mL
  ANCA                                Atypical     Negative
  MPO ANCA                            Negative     Negative
  PR3 ANCA                            Negative     Negative
  Globulins                           Normal       Normal
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